Skip to content

Placebo control study of lansoprazole for the treatment of functional dyspepsia in children

Double blind randomized placebo control study of lansoprazole for the treatment of functional dyspepsia in children

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/04/052031
Enrollment
120
Registered
2023-04-27
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K30- Functional dyspepsia

Interventions

None listed

Sponsors

Fourrts pharmaceutical company
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: FUNCTIONAL DYSPEPSIA (Roams 4 criteria) - Must include one or more of the following bothersome symptoms at least 4 times a month for at least 2 months prior to diagnosis: Postprandial fullness Early satiation Epigastric pain or burning not associated with defecation After appropriate evaluation, the symptoms cannot be fully explained by another medical condition Within FD(Functional dyspepsia) the following subtypes are now adopted: H2a1.  Postprandial distress syndrome includes bothersome postprandial fullness or early satiation which prevents finishing a regular meal. Supportive features include upper abdominal bloating, postprandial nausea, or excessive belching. H2a2.  Epigastric pain syndrome which includes all of the following: bothersome (severe enough to interfere with normal activities) pain or burning localized to the epigastrium. The pain is not generalized or localized to other abdominal or chest regions and is not relieved by defecation or passage of flatus. Supportive criteria can include (a) burning quality of the pain but without a retrosternal component, (b) commonly induced or relieved by ingestion of a meal but may occur while fasting.

Exclusion criteria

Exclusion criteria: 1.Patient already on treatment with Proton pump inhibitors (PPI) /H2RA, Prokinetics ,NSAIDS or within 1 week of study commencement 2.Previous Gastrointestinal surgery and diseases (e.g. â?? ulcerative colitis, crohnâ??s disease) 3.Chronic systemic illness (liver,heart,renal diseases) 4.History of H. Pylori infection and treatment in last 6 months

Design outcomes

Primary

MeasureTime frame
To compare the effect of lansoprazole vs placebo on participants for complete relief of epigastric pain and postprandial distress during the last 3 days of 4 week treatment Timepoint: 28 days

Secondary

MeasureTime frame
1).Relief from other gastrointestinal symptoms like : nausea ,upper abdominal bloating , excessive belching , heartburn at day 7 , 14 and 28 2).Evaluate the participants at day 7 and 14 for complete relief of epigastric pain and postprandial distress i.e. early improvement Timepoint: day 7 ,day 14 ,day 28

Countries

India

Contacts

Public ContactMohammad Saif Chaudhary

Eras lucknow medical college

drshrishbhatnagar@gmail.com9918208555

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026